EU pumps EUR 2.9 million into cancer diagnostics project

The European Commission has awarded a grant of EUR 2.9 million to the COBRED project.

Funded under the Sixth Framework Programme (FP6), the COBRED project will aim to find new biomarkers for two of the most common cancers: colon cancer and breast cancer.

According to Dr Laszlo Takacs, CSO of BioSystems International, and COBRED coordinator, "This unprecedented project has the power to discover new cancer diagnostics. I am happy to see the enthusiasm of participating clinicians at the cancer centres, and of scientists at the academic and industrial laboratories."

The project will seek to develop the novel diagnostics for patient follow-up (monitoring markers) by exploiting the capacity of three state-of-the-art high-throughput technologies in an integrated systems biology approach.

After three years, COBRED hopes to deliver a set of biomarker/diagnostic candidates verified in preclinical studies, ready for large scale clinical validation and further development for commercialisation.

Furthermore, COBRED will seek to demonstrate the potential of exploring data from different high-throughput technologies and clinical profiles with advanced data mining technologies.

COBRED will also examine biomarkers for follow-up diagnostics, as novel diagnostic candidates may have the potential to aid early cancer detection via population screening. Additionally, the data gathered as part of the study may highlight poorly understood cancer mechanisms.

As breast cancer is the most common cancer in European women, and colorectal cancer is the third most common cancer type worldwide, diagnostics based on biomarkers have the potential to significantly improve current cancer disease management and diagnosis, providing higher accuracy at a lower cost.

The project consortium hopes this will lead to direct benefits for patients and society as a whole.

In addition to BioSystems International, the consortium comprises two other biotechnology firms, two large comprehensive cancer centres, three universities and a consultancy firm.

The project website will be up and running soon at the following address:
http://www.cobred.eu

Copyright ©European Communities, 2007
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

Unlocking the 10 Year Health Plan

The government's plan for the NHS is a huge document. Jane Stephenson, chief executive of SPARK TSL, argues the key to unlocking its digital ambitions is to consider what it...

Alcidion Grows Top Talent in the UK, wit…

Alcidion has today announced the addition of three new appointments to their UK-based team, with one internal promotion and two external recruits. Dr Paul Deffley has been announced as the...

AI can Find Cancer Pathologists Miss

Men assessed as healthy after a pathologist analyses their tissue sample may still have an early form of prostate cancer. Using AI, researchers at Uppsala University have been able to...

AI, Full Automation could Expand Artific…

Automated insulin delivery (AID) systems such as the UVA Health-developed artificial pancreas could help more type 1 diabetes patients if the devices become fully automated, according to a new review...

How AI could Speed the Development of RN…

Using artificial intelligence (AI), MIT researchers have come up with a new way to design nanoparticles that can more efficiently deliver RNA vaccines and other types of RNA therapies. After training...

MIT Researchers Use Generative AI to Des…

With help from artificial intelligence, MIT researchers have designed novel antibiotics that can combat two hard-to-treat infections: drug-resistant Neisseria gonorrhoeae and multi-drug-resistant Staphylococcus aureus (MRSA). Using generative AI algorithms, the research...

AI Hybrid Strategy Improves Mammogram In…

A hybrid reading strategy for screening mammography, developed by Dutch researchers and deployed retrospectively to more than 40,000 exams, reduced radiologist workload by 38% without changing recall or cancer detection...

Penn Developed AI Tools and Datasets Hel…

Doctors treating kidney disease have long depended on trial-and-error to find the best therapies for individual patients. Now, new artificial intelligence (AI) tools developed by researchers in the Perelman School...

New Training Year Starts at Siemens Heal…

In September, 197 school graduates will start their vocational training or dual studies in Germany at Siemens Healthineers. 117 apprentices and 80 dual students will begin their careers at Siemens...

Are You Eligible for a Clinical Trial? C…

A new study in the academic journal Machine Learning: Health discovers that ChatGPT can accelerate patient screening for clinical trials, showing promise in reducing delays and improving trial success rates. Researchers...

New AI Tool Addresses Accuracy and Fairn…

A team of researchers at the Icahn School of Medicine at Mount Sinai has developed a new method to identify and reduce biases in datasets used to train machine-learning algorithms...

Global Study Reveals How Patients View M…

How physicians feel about artificial intelligence (AI) in medicine has been studied many times. But what do patients think? A team led by researchers at the Technical University of Munich...